Update to Resiliency Roadmap for FDA Inspectional Oversight

As of September 30, 2021, FDA has exceeded the Base-Case Scenario projections for FY21, completing more than twice as many domestic surveill

Receive this email as a forward? Subscribe to CDER SBIA industry updates. FDA | CDER | Small Business and Industry Assistance INDUSTRY NEWS . Update to Resiliency Roadmap for FDA Inspectional Oversight   Today, FDA released an update to the "Resiliency Roadmap for FDA Inspectional Oversight" report. As of September 30, 2021, FDA has exceeded the Base-Case Scenario projections for FY21, completing more than twice as many domestic surveillance oversight activities than projected in the Roadmap. FDA's development of new oversight approaches and expanded use of a variety of surveillance tools significantly contributed to the agency's ability to exceed these goals. This enabled the agency to provide oversight to as many facilities as possible, while utilizing our resources to protect consumers and patients and promote public health.   Learn More The Small Business and Industry Assistance (SBIA) program in the Center for Drug Evaluation and Research  provides guidance, education and updates for regulated industry. Subscribe to CDER SBIA Email Updates Register for Upcoming Training View 2021 Recordings on YouTube Follow on LinkedIn Follow on Twitter This is an automated message delivery system. Replying to this message will not reach the CDER SBIA staff. If you have comments or questions, contact us at CDERSBIA@fda.hhs.gov or 1-866-405-5367 or (301) 796-6707.  SUBSCRIBER SERVICES: Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA